Sanofi Partners With Evotec to Develop Diabetes Therapies
07 August 2015 - 4:24PM
Dow Jones News
By Matthew Dalton
PARIS--Sanofi S.A. on Friday said it will work with German
biotech company Evotec AG to develop a new class of medicines to
treat diabetes.
Sanofi could pay Evotec up to EUR300 million ($327.8 million)
for hitting various drug development milestones, plus additional
royalties on net sales of the drugs.
The collaboration will use human stem cells to develop drugs
that bolster "Beta" cells, which release insulin and become
impaired in people with diabetes. The drugs could reduce the need
for diabetes patients to inject themselves with insulin, Sanofi
said.
Write to Matthew Dalton at matthew.dalton@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2024 to May 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From May 2023 to May 2024